Merck & Co., Inc. hit a key milestone in advancing its cardiovascular pipeline on 10 October, announcing a successful Phase III trial for sotatercept, a reverse-remodeling agent proposed to rebalance TGF-beta superfamily signaling, in mid-stage pulmonary arterial hypertension (PAH) patients. The pharma said it will move “with urgency” in speaking with regulators about an approval pathway for sotatercept.
Merck’s Sotatercept Hits Phase III Marks In Mid-Stage PAH Patients
The pharma’s pulmonary arterial hypertension candidate, touted as a future blockbuster seller, showed benefit on six-minute walk distance and several secondary endpoints in Phase III STELLAR.
